instruction:
Given a passage with a question and an answer to that question, classify if the answer actually answers the question into 'yes' or 'no'. Output 'yes' if the answer answers the question and output 'no' if the answer does not answer the question.
question:
Question: Are clinical and serum-based markers associated with death within 1 year of de novo implant in primary prevention ICD recipients?
Answer: Individuals with more comorbidities and elevation of specific serum biomarkers were at increased risk of all-cause mortality despite being deemed as having a reasonable 1-year life expectancy. A simple risk score composed of readily available clinical data and serum biomarkers may better identify patients at high risk of early mortality and improve patient selection and counseling for primary prevention ICD therapy.
answer:
yes


question:
Question: Does pTEN loss in biopsy tissue predict poor clinical outcomes in prostate cancer?
Answer: PTEN loss at the time of biopsy seems to predict time to development of metastasis, prostate cancer-specific mortality and, for the first time, castration-resistant prostate cancer and response to androgen deprivation therapy after radical prostatectomy. If confirmed by larger studies, this would support the use of PTEN loss as an early marker of aggressive prostate cancer.
answer:
yes


question:
Question: Are omeprazole and lansoprazole inducers of cytochrome P4501A2 under conventional therapeutic conditions?
Answer: The results show that both omeprazole and lansoprazole in the daily recommended therapeutic doses of 20 mg and 30 mg, respectively, have no influence on the metabolism of caffeine, and therefore no influence on cytochrome CYP1A2 activity.
answer:

no